Treating cardiovascular disease (CVD) risk factors, including dyslipidemia, is important in HIV care. Low-density lipoprotein cholesterol (LDL-c) target achievement is a readily available benchmark for dyslipidemia control, although use of this target is not uniformly endorsed by professional societies. We examined whether HIV serostatus is associated with not achieving LDL-c target. Among Multicenter AIDS Cohort Study (MACS) participants completing visit 56 (10/1/2011–3/31/2012), we categorized each man as on or off statin therapy and used NCEP ATP III guidelines to determine if each man was at LDL-c target or not at target. We compared proportions of men not at target and determined predictors using multivariate logistic regression. Sixty of 543 (11.1%) HIV-infected men and 87 of 585 (14.9%) HIV-uninfected men not receiving statin therapy were not at target (p=0.07), while 31 of 230 (13.5%) HIV-infected and 29 of 204 (14.2%) HIV-uninfected men receiving statin therapy were not at target (p=0.82). Factors associated with not being at target (among men not receiving statin therapy) included current smoking (OR=2.31, 95% CI 1.31, 4.06) and a diagnosis of hypertension (OR=4.69, 95% CI 2.68, 8.21). Factors associated with not being at target (among men receiving statin therapy) included current smoking (OR=2.72, 95% CI 1.30, 5.67) and diabetes (OR=5.31, 95% CI 2.47, 11.42). HIV-infected and HIV-uninfected men receiving statin therapy demonstrated similar nonachievement of LDL-c targets. Comorbidities (e.g., diabetes) lowered targets and may explain why goals were less likely to be met.
Get full access to this article
View all access options for this article.
References
1.
PalellaFJJr, BakerRK, MoormanAC, et al.: Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr, 2006; 43(1):27–34.
2.
SterneJAC, HernánMA, LedergerberB, et al.: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet, 2005; 366 (9483):378–384.
3.
BarbaroG: Highly active antiretroviral therapy-associated metabolic syndrome: Pathogenesis and cardiovascular risk. Am J Ther, 2006; 13(3):248–260.
4.
WadaN, JacobsonLP, CohenM, et al.: Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984–2008. Am J Epidemiol, 2013; 177(2):116–125.
5.
SavesM, ChêneG, DucimetiereP, et al.: Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis, 2003; 37:292–298.
6.
TriantV, LeeH, HadiganC, and GrinspoonS: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab, 2007; 92(7):2506–2512.
7.
CurrierJ, TaylorA, BoydF, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr, 2003; 33(4):506–512.
8.
FreibergMS, ChangCCH, SkandersonM, et al.: The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circulation, 2011; 4(4):425–432.
9.
PalellaFJJr, BakerRK, BuchaczK, et al.: Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS, 2011; 25(15):1865–1876.
10.
SackoffJE, HannaDB, PfeifferMR, and TorianLV: Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med, 2006; 145(6):397–406.
11.
BrownTT, ColeSR, LiX, et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med, 2005; 165(10):1179–1184.
12.
De WitS, SabinCA, WeberR, et al.: Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care, 2008; 31(6):1224–1229.
13.
BaekkenM, OsI, SandvikL, and OektedalenO: Hypertension in an urban HIV-positive population compared with the general population: Influence of combination antiretroviral therapy. J Hypertens, 2008; 26(11):2126–2133.
14.
SatlinMJ, HooverDR, and GlesbyMJ: Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS, 2011; 25(1):5–12.
15.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation, 2002; 106(25):3143–3421.
16.
GrundySM, CleemanJI, MerzCNB, et al.: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol, 2004; 44(3):720–732.
17.
AndersonKM, WilsonP, OdellPM, and KannelWB: An updated coronary risk profile. A statement for health professionals. Circulation, 1991; 83(1):356–362.
18.
BaigentC, KeechA, KearneyPa, et al.: Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366(9493):1267–1278.
19.
ZafrirB and CohenS: Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Eur J Int Med, 2006; 17(7):495–499.
20.
PearsonTA: The undertreatment of LDL-cholesterol: Addressing the challenge. Int J Cardiol, 2000; 74:S23–S28.
21.
StoneNJ, RobinsonJ, LichtensteinAH, et al.: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63(25 Pt B):2889–2934.
22.
JellingerPS, SmithDA, MehtaAE, et al.: American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocrine Practice, 2012; 18:1–78.
23.
American Association of Clinical Endocrinologists (AACE): Press statement. http://media.aace.com/press-release/press-statement. Accessed March27, 2014.
24.
ReinschN, NeuhausK, EsserS, et al.: Are HIV patients undertreated? Cardiovascular risk factors in HIV:R of the HIV-HEART study. Eur J Prev Card, 2012; 19(2):267–274.
25.
NüeschR, WangQ, ElziL, et al.: Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). JAIDS J Acquir Immune Defic Syndr, 2013; 62(4):396–404.
26.
KaslowRA, OstrowDG, DetelsR, et al.: The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants. Am J Epidemiol, 1987; 126(2):310–318.
27.
FriedewaldWT, LevyRI, and FredricksonDS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18(6):499–502.
28.
AllainCC, PoonLS, ChanCS, et al.: Enzymatic determination of total serum cholesterol. Clin Chem, 1974; 20(4):470–475.
29.
WarnickGR and AlbersJ: A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res, 1978; 19(1):65–76.
30.
BucoloG, YabutJ, and ChangTY: Mechanized enzymatic determination of triglycerides in serum. Clin Chem, 1975; 21(3):420–424.
31.
SchoutenJ, WitFW, StolteIG, et al.: Comorbidity and ageing in HIV-1 infection: The AGEhIV Cohort Study. XIX International AIDS Conference. July 22–27, 2012. Washington, DC. Abstract THAB0205.
32.
LichtensteinKA, ArmonC, BuchaczK, et al.: Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chron Dis, 2013; 10:E10.
33.
CasagrandeSS, FradkinJE, SaydahSH, et al.: The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care, 2013; 36(8):2271–2279.
34.
BantaMR, MaF, BravataDM, et al.: Incidence of and factors associated with achieving target lipid levels in patients with peripheral arterial disease. J Gen Intern Med, 2006; 21(7):711–714.
35.
RiddlerS, LiX, ChuH, et al.: Longitudinal changes in serum lipids among HIV‐infected men on highly active antiretroviral therapy. HIV Med, 2007; 8(5):280–287.
36.
SubramanianS, TawakolA, BurdoTH, et al.: Arterial inflammation in patients with HIV. JAMA, 2012; 308(4):379–386.
37.
ZanniMV, AbbaraS, LoJ, et al.: Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS, 2013; 27(8):1263–1272.
38.
CramerJA, ScheyerRD, and MattsonRH: Compliance declines between clinic visits. Arch Intern Med, 1990; 150(7):1509–1510.
39.
DownsJR, ClearfieldM, WeisS, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA, 1998; 279(20):1615–1622.
40.
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 2002; 360(9326):7–22.
41.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet, 1994; 344(8934):1383–1389.
42.
United States Food and Drug Administration: FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed March27, 2014.
GibsonK and RindoneJP: Experience with statin use in patients with chronic hepatitis C infection. Am J Cardiol, 2005; 96(9):1278–1279.
46.
KhorashadiS, HassonNK, and CheungRC: Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol, 2006; 4(7):902–907.
47.
ChalasaniN, AljadheyH, KestersonJ, et al.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 2004; 126(5):1287–1292.
48.
StroupJS and HarrisB: Is statin therapy safe in patients with HIV/hepatitis C coinfection?. Proc (Bayl Univ Med Cent), 2010; 23(2):111–113.
49.
MilazzoL, MenzaghiB, CorvasceS, et al.: Safety of statin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr, 2007; 46(2):258–260.
50.
AthyrosVG, TziomalosK, GossiosTD, et al.: Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet, 2010; 376(9756):1916–1922.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
